+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Cystic Fibrosis Therapeutics Market by Drug Class and Route of Administration: Global Opportunity Analysis and Industry Forecast, 2019-2026

  • ID: 4989535
  • Report
  • November 2019
  • Region: Global
  • 187 pages
  • Allied Analytics LLP
1 of 5

Enquire about COVID-19 updates for this product.

Enquire Now

FEATURED COMPANIES

  • AbbVie Inc.
  • Allergan plc
  • Genentech Inc.
  • Gilead Sciences Inc.
  • GlaxoSmithKline Plc.
  • Johnson & Johnson
  • MORE
The global cystic fibrosis therapeutics market was valued at $4,615.4 million in 2018 and is expected to reach $9,277.3 million by 2026, registering a CAGR of 9.2% from 2019 to 2026. Cystic fibrosis is a progressive, hereditary disease that led to insistent lung infections and limits the patient’s ability to breathe over time. Diagnosis of cystic fibrosis is a multistep process, and includes a newborn screening, a sweat test, a genetic or carrier test, and a clinical evaluation. Though people diagnosed with the disease are of age of 2, some are also diagnosed as adults. A specialist can order a sweat test and recommend additional testing to confirm the diagnosis.

Significant rise in incidence of cystic fibrosis across the globe and increase in awareness about its diagnosis are the major factors driving the market growth. In addition, rise in R&D investments by the key players such as Vertex Pharmaceuticals propels the growth of cystic fibrosis therapeutics market. However, high cost of the cystic fibrosis treatment and introduction of generic drugs hinder the growth of the market. Moreover, development of the healthcare industry and increase in R&D activities undertaken by key players are expected to boost the market growth during the forecast period. Furthermore, rise in prevalence of cystic fibrosis has generated need for newer and advanced therapeutics for its treatment. Thereby, this has led to increase in number of pipeline drugs in the market, which is expected to provide remunerative opportunities for market expansion during the forecast period.

The global cystic fibrosis therapeutic market is segmented based on drug class, route of administration, top selling drug, and region. On the basis of drug class, the market is divided into pancreatic enzyme supplements, mucolytic, bronchodilators, and CFTR modulators. Depending on route of administration, it is classified into oral and inhaled. Region wise, it is analyzed across North America, Europe, Asia-Pacific, and LAMEA.

KEY BENEFITS FOR STAKEHOLDERS
  • The study provides an in-depth analysis of the market along with the current trends and future estimations to elucidate the imminent investment pockets.
  • It offers a quantitative analysis from 2018 to 2026, which is expected to enable the stakeholders to capitalize on prevailing market opportunities.
  • Comprehensive analysis of all geographical regions is provided to determine the prevailing opportunities.
  • Key players are profiled, and their strategies are analyzed thoroughly to understand the competitive outlook of the global market.
KEY MARKET SEGMENTS

By Drug Class
  • Pancreatic Enzyme Supplements
  • Mucolytic
  • Bronchodilators
  • CFTR Modulators
By Route of Administration
  • Oral
  • Inhaled
By Region
  • North America
  • U.S.
  • Canada
  • Mexico
  • Europe
  • Germany
  • France
  • UK
  • Italy
  • Rest of Europe
  • Asia Pacific
  • Japan
  • China
  • India
  • Australia
  • Rest of Asia-Pacific
  • LAMEA
  • Brazil
  • Saudi Arabia
  • South Africa
  • Rest of LAMEA
LIST OF KEY PLAYERS PROFILED IN THE REPORT
  • Genentech, Inc.
  • Novartis AG
  • Gilead Sciences, Inc.
  • Vertex Pharmaceuticals Incorporated
  • AbbVie Inc.
  • GlaxoSmithKline Plc.
  • Johnson & Johnson
  • Allergan plc.
  • Pharmaxis Ltd.
  • Mylan N.V.
Note: Product cover images may vary from those shown
2 of 5

FEATURED COMPANIES

  • AbbVie Inc.
  • Allergan plc
  • Genentech Inc.
  • Gilead Sciences Inc.
  • GlaxoSmithKline Plc.
  • Johnson & Johnson
  • MORE
Chapter 1: Introduction
1.1. Report Description
1.2. Key Benefits For Stakeholders
1.3. Key Market Segments
1.4. Research Methodology
1.4.1. Secondary Research
1.4.2. Primary Research
1.4.3. Analyst Tools & Models

Chapter 2: Executive Summary
2.1. CXO Perspective

Chapter 3: Market Overview
3.1. Market Definition And Scope
3.2. Porter’s Five Forces Analysis
3.3. Top Player Positioning
3.4. Market Dynamics
3.4.1. Drivers
3.4.1.1. Rise In Incidence Of Cystic Fibrosis (Cf)
3.4.1.2. Advancements In Therapeutics For Treatment Of Cystic Fibrosis
3.4.2. Restraints
3.4.2.1. Low Awareness In Developing Nations
3.4.3. Opportunity
3.4.3.1. Surge In R&D Towards The Development Of Novel Therapeutics

Chapter 4: Cystic Fibrosis Therapeutics Market, By Drug Class
4.1. Overview
4.1.1. Market Size And Forecast
4.2. Pancreatic Enzyme Supplements
4.2.1. Key Market Trends And Opportunities
4.2.2. Market Size And Forecast
4.2.3. Market Analysis, By Country
4.3. Mucolytics
4.3.1. Key Trends And Opportunities
4.3.2. Market Size And Forecast
4.3.3. Market Analysis, By Country
4.4. Bronchodilators
4.4.1. Key Market Trends And Opportunities
4.4.2. Market Size And Forecast
4.4.3. Market Analysis, By Country
4.5. Cftr Modulators
4.5.1. Key Trends And Opportunities
4.5.2. Market Size And Forecast
4.5.3. Market Analysis, By Country

Chapter 5: Cystic Fibrosis Therapeutics Market, By Route Of Administration
5.1. Overview
5.1.1. Market Size And Forecast
5.2. Oral
5.2.1. Market Size And Forecast
5.2.2. Market Analysis, By Country
5.3. Inhale
5.3.1. Market Size And Forecast
5.3.2. Market Analysis, By Country

Chapter 6: Cystic Fibrosis Therapeutics Market, By Region
6.1. Overview
6.1.1. Market Size And Forecast
6.2. North America
6.2.1. Key Trends And Opportunities
6.2.2. North America Market Size And Forecast, By Country
6.2.2.1. U.S. Market Size And Forecast, By Drug Class
6.2.2.2. U.S. Market Size And Forecast, By Route Of Administration
6.2.2.3. Canada Market Size And Forecast, By Drug Class
6.2.2.4. Canada Market Size And Forecast, By Route Of Administration
6.2.2.5. Mexico Market Size And Forecast, By Drug Class
6.2.2.6. Mexico Market Size And Forecast, By Route Of Administration
6.2.3. North America Market Size And Forecast, By Drug Class
6.2.4. North America Market Size And Forecast, By Route Of Administration
6.3. Europe
6.3.1. Key Trends And Opportunities
6.3.2. Europe Market Size And Forecast, By Country
6.3.2.1. Germany Market Size And Forecast, By Drug Class
6.3.2.2. Germany Market Size And Forecast, By Route Of Administration
6.3.2.3. UK Market Size And Forecast, By Drug Class
6.3.2.4. UK Market Size And Forecast, By Route Of Administration
6.3.2.5. France Market Size And Forecast, By Drug Class
6.3.2.6. France Market Size And Forecast, By Route Of Administration
6.3.2.7. Rest Of Europe Market Size And Forecast, By Drug Class
6.3.2.8. Rest Of Europe Market Size And Forecast, By Route Of Administration
6.3.3. Europe Market Size And Forecast, By Drug Class
6.4. Asia-Pacific
6.4.1. Key Trends And Opportunities
6.4.2. Asia-Pacific Market Size And Forecast, By Country
6.4.2.1. Japan Market Size And Forecast, By Drug Class
6.4.2.2. Japan Market Size And Forecast, By Route Of Administration
6.4.2.3. China Market Size And Forecast, By Drug Class
6.4.2.4. China Market Size And Forecast, By Route Of Administration
6.4.2.5. India Market Size And Forecast, By Drug Class
6.4.2.6. India Market Size And Forecast, By Route Of Administration
6.4.2.7. Australia Market Size And Forecast, By Drug Class
6.4.2.8. Australia Market Size And Forecast, By Route Of Administration
6.4.2.9. Rest Of Asia-Pacific Market Size And Forecast, By Drug Class
6.4.2.10. Rest Of Asia-Pacific Market Size And Forecast, By Route Of Administration
6.4.3. Asia-Pacific Market Size And Forecast, By Drug Class
6.4.4. Asia-Pacific Market Size And Forecast, By Route Of Administration
6.5. LAMEA
6.5.1. Key Market Trends And Opportunities
6.5.2. LAMEA Market Size And Forecast, By Country
6.5.2.1. Brazil Market Size And Forecast, By Drug Class
6.5.2.2. Brazil Market Size And Forecast, By Route Of Administration
6.5.2.3. South Africa Market Size And Forecast, By Drug Class
6.5.2.4. South Africa Market Size And Forecast, By Route Of Administration
6.5.2.5. Saudi Arabia Market Size And Forecast, By Drug Class
6.5.2.6. Saudi Arabia Market Size And Forecast, By Route Of Administration
6.5.2.7. Rest Of LAMEA Market Size And Forecast, By Drug Class
6.5.2.8. Rest Of LAMEA Market Size And Forecast, By Route Of Administration
6.5.3. LAMEA Market Size And Forecast, By Drug Class
6.5.4. LAMEA Market Size And Forecast, By Route Of Administration

Chapter 7: Company Profiles
7.1. F. Hoffmann-La Roche Ag
7.1.1. Company Overview
7.1.2. Company Snapshot
7.1.3. Operating Business Segments
7.1.4. Product Portfolio
7.1.5. Business Performance
7.2. Novartis Ag
7.2.1. Company Overview
7.2.2. Company Snapshot
7.2.3. Operating Business Segments
7.2.4. Product Portfolio
7.2.5. Business Performance
7.3. Gilead Sciences, Inc.
7.3.1. Company Overview
7.3.2. Company Snapshot
7.3.3. Operating Business Segments
7.3.4. Product Portfolio
7.3.5. Business Performance
7.4. Vertex Pharmaceuticals Incorporated
7.4.1. Company Overview
7.4.2. Company Snapshot
7.4.3. Operating Business Segments
7.4.4. Product Portfolio
7.4.5. Business Performance
7.4.6. Key Strategic Moves And Developments
7.5. Abbvie Inc.
7.5.1. Company Overview
7.5.2. Company Snapshot
7.5.3. Operating Business Segments
7.5.4. Product Portfolio
7.5.5. Business Performance
7.5.6. Key Strategic Moves And Developments
7.6. Glaxosmithkline Plc.
7.6.1. Company Overview
7.6.2. Company Snapshot
7.6.3. Operating Business Segments
7.6.4. Product Portfolio
7.6.5. Business Performance
7.7. Teva Pharmaceutical Industries Ltd.
7.7.1. Company Overview
7.7.2. Company Snapshot
7.7.3. Operating Business Segments
7.7.4. Product Portfolio
7.7.5. Business Performance
7.8. Allergan Plc
7.8.1. Company Overview
7.8.2. Company Snapshot
7.8.3. Operating Business Segments
7.8.4. Product Portfolio
7.8.5. Business Performance
7.9. Pharmaxis Ltd
7.9.1. Company Overview
7.9.2. Company Snapshot
7.9.3. Operating Business Segments
7.9.4. Product Portfolio
7.10. Mylan N.V
7.10.1. Company Overview
7.10.2. Company Snapshot
7.10.3. Operating Business Segments
7.10.4. Product Portfolio
7.10.5. Business Performance

*Full List of Tables and Figures Available on Enquiry.
Note: Product cover images may vary from those shown
3 of 5

Loading
LOADING...

4 of 5

FEATURED COMPANIES

  • AbbVie Inc.
  • Allergan plc
  • Genentech Inc.
  • Gilead Sciences Inc.
  • GlaxoSmithKline Plc.
  • Johnson & Johnson
  • MORE
According to the report titled, 'Cystic Fibrosis Therapeutics Market by Drug Class and Route of Administration: Global Opportunity Analysis and Industry Forecast, 2018-2026', the global cystic fibrosis therapeutics market size is expected to reach $9,277 million by 2026, registering a CAGR of 9.2% from 2019 to 2026, in terms of value.

Cystic fibrosis is a hereditary disease that majorly affects the lungs and digestive system. In cystic fibrosis, the body produces thick and sticky mucus that may block the lungs and impede the pancreas. The disease can be lethal, and patients tend to have a shorter-than-normal life span. Further, the disease is so dangerous that all newborns in the U.S. are screened for CF. Moreover, there is no cure for cystic fibrosis, but taking proper nutrition and medications to thin excess mucus produced in lungs & kidney can help in increasing patient’s lifespan. In addition, treatment of cystic fibrosis includes the use of drugs such as Pulmozyme, Kalydeco, and others. These drugs can be administered to the patient by different routes such as oral and by inhalation.

Rise in incidence of cystic fibrosis across the globe and increase in medications against cystic fibrosis are the major factors driving the market growth. Moreover, rise in R&D investments toward the development of drugs to treat cystic fibrosis propels the cystic fibrosis therapeutics market growth. However, high cost of the cystic fibrosis treatment and introduction of generic drugs hinder the growth of the market. Moreover, development of the healthcare industry in the developing economies are expected to create lucrative opportunities in the near future. Furthermore, rise in prevalence of cystic fibrosis has generated need for newer and advanced therapeutics for its treatment. Hence, this has led to increase in number of pipeline drugs in the market, which is expected to provide remunerative opportunities for market expansion during the forecast period.

By cystic fibrosis therapeutics market analysis, based on drug class, the CFTR modulators segment dominated the market in 2018 and is anticipated to continue its dominance during the forecast period. This is attributed to increased usage of these drugs for the treatment of cystic fibrosis. Further, these drugs target the production and function of the mutant CFTR protein. In addition, the CFTR protein regulates the flow of water and chloride in and out of cells lining the lungs and other organs. These drugs are being considered as potent therapeutics for the treatment of the disease. The three major types of modulators are potentiators, correctors, and amplifiers.

By route of administration, oral segment accounted for the majority of market share in 2018, owing to increased formulation of cystic fibrosis therapeutics in oral form. Further, there are currently three CFTR modulator drugs approved by the U.S. FDA, all of which are oral tablets. These include ivacaftor (kalydeco), orkambi and symdeko. As per the current cystic fibrosis therapeutics market trend, the oral route of administration is estimated to grow at the fastest growth rate during the forecast period.

Key Findings of the Cystic Fibrosis Therapeutics Market:
By drug class, the CFTR segment accounted for the highest market share of 65% in 2018 and is anticipated to grow at the fastest rate during the forecast period.
By region, Europe was the major shareholder and accounted for the highest share of 33% in 2018.
By route of administration, oral segment is expected to grow at a CAGR of 9.9% during the forecast period.
North America is anticipated to grow at the fastest CAGR of 9.8% during the forecast period.
Key players operating in cystic fibrosis therapeutic markets are Genentech, Inc., Novartis AG, Gilead Sciences, Inc., Vertex Pharmaceuticals Incorporated, AbbVie Inc., GlaxoSmithKline Plc., Johnson & Johnson, Allergan plc, Pharmaxis Ltd., and Mylan N.V.
Note: Product cover images may vary from those shown
5 of 5
  • Genentech Inc.
  • Novartis AG
  • Gilead Sciences Inc.
  • Vertex Pharmaceuticals Incorporated
  • AbbVie Inc.
  • GlaxoSmithKline Plc.
  • Johnson & Johnson
  • Allergan plc
  • Pharmaxis Ltd.
  • Mylan N.V.
Note: Product cover images may vary from those shown
6 of 5

The analyst offers exhaustive research and analysis based on a wide variety of factual inputs, which largely include interviews with industry participants, reliable statistics, and regional intelligence. The in-house industry experts play an instrumental role in designing analytic tools and models, tailored to the requirements of a particular industry segment. The primary research efforts include reaching out participants through mail, tele-conversations, referrals, professional networks, and face-to-face interactions.

They are also in professional corporate relations with various companies that allow them greater flexibility for reaching out to industry participants and commentators for interviews and discussions.

They also refer to a broad array of industry sources for their secondary research, which typically include; however, not limited to:

  • Company SEC filings, annual reports, company websites, broker & financial reports, and investor presentations for competitive scenario and shape of the industry
  • Scientific and technical writings for product information and related preemptions
  • Regional government and statistical databases for macro analysis
  • Authentic news articles and other related releases for market evaluation
  • Internal and external proprietary databases, key market indicators, and relevant press releases for market estimates and forecast

Furthermore, the accuracy of the data will be analyzed and validated by conducting additional primaries with various industry experts and KOLs. They also provide robust post-sales support to clients.

Loading
LOADING...

Adroll
adroll